8-K 1 a00181e8vk.htm FORM 8-K Aastrom Biosciences, Inc.
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of earliest event reported)
  July 6, 2004
 
 

Aastrom Biosciences, Inc.

(Exact name of registrant as specified in charter)
         
Michigan   0-22025   94-3096597
 
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
         
24 Frank Lloyd Wright Drive, P.O. Box 376, Ann Arbor, Michigan   48106
 
(Address of principal executive offices)   (Zip Code)
     
Registrant’s telephone number, including area code
  (734) 930-5555
 
 

Not Applicable

(Former name or former address, if changed since last report)

 

TABLE OF CONTENTS

Item 5. Other Events.
Item 7. Financial Statements and Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

Table of Contents

Item 5. Other Events.

On July 6, 2004, Aastrom Biosciences issued a press release relating to the appointment of James A. Cour as its new President and Chief Operating Officer. The press release is attached as Exhibit 99.1.

Item 7. Financial Statements and Exhibits.

     
Exhibit    
No.
   Description
99.1
  Press Release of July 6, 2004.

 

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Aastrom Biosciences, Inc.
 
        
Date: July 7, 2004
  By:   /s/ Alan M. Wright
     
 
      Senior Vice President,
 
       Administrative and Financial Operations, CFO

 

Table of Contents

EXHIBIT INDEX

     
Exhibit    
No.
   Description
99.1
  Press Release of July 6, 2004.